🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Practo delivers 3,500 Cr GMV in FY24; narrows EBITDA losses by 82%

EntrackrEntrackr · 11m ago
Practo delivers 3,500 Cr GMV in FY24; narrows EBITDA losses by 82%
Medial

Practo surpassed a GMV (gross merchandise value) of over Rs 3,500 crore in the fiscal year ending March 2024. The company also recorded a 22% year-on-year increase in operating revenue, while operating EBITDA losses reduced by 82% during FY24. Practo’s revenue from operations increased to Rs 240 crore in FY24, reflecting a 22% increase when compared to FY23, the company’s press release shows. Practo helps patients find and connect with the right healthcare providers. It is a platform to find quality & verified healthcare services enabling patients to make informed decisions through an array of processes such as audits of facilities, verification of doctors credentials, merit-based scoring system for providers, patient reviews etc. It also provides software for hospitals and clinics to improve the efficiency of facilities. According to the blog post on the company’s website, it has served over 54 million patients across 642 cities and has done more than 600 healthcare establishment (hospital) audits during the previous fiscal. Practo’s focused approach to its core India business resulted in a 68% CAGR (compound annual growth rate) between FY22 and FY24, while its contribution margin improved significantly, rising from -1% in FY22 to 40% in FY24, according to the press release. “Our goal has always been to improve healthcare outcomes while building a sustainable business. Our sharp focus on the core business has driven exceptional results. Practo is excited to continue this momentum, with ambitious plans for growth with profitability in the coming year”, Shashank ND, Co-founder and CEO, of Practo, added. The growth and controlled expenditure helped Practo to reduce its EBIDTA losses by 82% to Rs 17 crore in FY24 from Rs 99.4 crore in FY23. As per the company, the last quarter (Q4) of FY24 was profitable and claimed profitability over the preceding 12 months ending September 2024. Practo is also exploring global expansion to extend its healthcare services beyond India. Practo has raised a total of $179 million to date from investors including Peak XV Partners, Matrix Partners (Z47), Tencent, and AIA. It competes with Pristyn Care-owned Lybrate, Medibuddy, and Healthians, among others.

Vyapar posts Rs 63 Cr loss in FY25; cash reserve fades 93%

EntrackrEntrackr · 1m ago
Vyapar posts Rs 63 Cr loss in FY25; cash reserve fades 93%
Medial

Vyapar posts Rs 63 Cr loss in FY25; cash reserve fades 93% Vyapar’s operating revenue rose 53% year-on-year to Rs 69 crore in FY25, up from Rs 45 crore in FY24, according to its consolidated financial statements filed with the Registrar of Companies (RoC). Business accounting software provider Vyapar continued to operate deep in the red in FY25 even as it expanded its year-on-year scale. The Delhi-based company’s losses remained high, though they narrowed, and its cash buffer eroded significantly during the last fiscal year. Founded in 2018, Vyapar helps SMEs keep track of their receivables and payables, inventory management, send customized invoices, payment reminders and transaction messages in multiple languages. Revenue from the sale of its software’s license accounted for 90% of the income while the rest came from provision of its services (subscriptions fee). Employee benefits remained the company’s largest cost component accounting for 72% of the total expense. This expense increased 11% to Rs 102 crore in FY25 from Rs 92 crore in FY24. Other operating overheads such as customer support cost, rent, marketing, etc added the remaining Rs 39 crore to the total income which increased by 11% year-on-year to Rs 141 crore in FY25 from Rs 127.5 crore in FY24. At the bottom line, the company reduced its net loss by 13% to Rs 63 crore, compared to Rs 72.6 crore in FY24. Its ROCE and EBITDA margin stood at -62.61% and -102.9% respectively. On a unit basis, the company spent Rs 2.04 to earn a rupee of operating revenue in FY25. The company’s current assets decreased to Rs 89 crore in FY25 from Rs 141 crore in FY24. Its cash and bank balance was cut by 93% to Rs 6 crore in FY25 from Rs 91 crore in FY24. Vyapar has raised a total of $36 million of funding till date, having Indiamart and WestBridge as its lead investors which owns 25.5% and 16% of the company respectively.

Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37%

EntrackrEntrackr · 5d ago
Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37%
Medial

MediBuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37% Following more than 2X growth in the fiscal year ending March 2024, digital healthcare platform MediBuddy reported modest growth in its operating scale in FY25, while managing to narrow its losses by 37% during the period. MediBuddy's operating revenue grew 12.3% year-on-year to Rs 724.6 crore in FY25 from Rs 645.4 crore in the previous fiscal year (FY24), according to the company's annual financial statements filed with the Registrar of Companies (RoC). MediBuddy, a digital healthcare platform, provides online and offline medical consultations, medicine delivery, lab tests, surgeries, and insurance services, with revenue from these forming the primary source of income at Rs 722 crore, supplemented by Rs 2.5 crore from other operating sources. The company also earned Rs 18.42 crore from non-operating sources, including interest on fixed deposits and current investments, written-off liabilities, and other miscellaneous income, pushing its total income to Rs 743 crore in FY25. On expenses, the cost of materials was the largest at 38% of total expenses, standing at Rs 333 crore. Employee benefits expenses rose marginally by 8% to Rs 176.8 crore, including Rs 6 crore in ESOP expenses. Sales payout expenses, including commissions to selling agents, fell 7% to Rs 155.47 crore. The company spent Rs 42.5 crore on safety and security and Rs 32.5 crore on IT. Other overheads, including legal and professional fees, advertising, depreciation and amortization, and finance costs, amounted to Rs 138.7 crore. Overall expenses for the Bengaluru-based firm remained flat at Rs 879 crore, with controlled expenditure and a 12% rise in revenue helping to narrow losses by 37% to Rs 137 crore from Rs 215.7 crore in FY24. On a unit basis, MediBuddy spent Rs 1.21 to earn one rupee of operating revenue, with its EBITDA margin improving to -14.19% in FY25 from -25.67% in the previous year, resulting in an EBITDA loss of Rs 103 crore. As of March 2024, MediBuddy's current assets were Rs 395.2 crore, including cash and bank balances of Rs 80 crore. MediBuddy has raised over $190 million to date, last raising $18 million in August 2023 from existing investors Quadria Capital, Lightrock, and TEAMFund. It competes with companies including Pristyn Care-owned Lybrate, Practo, and mFine Tata 1mg.

EaseMyTrip posts Rs 150 Cr revenue in Q3 FY25; profit declines

EntrackrEntrackr · 10m ago
EaseMyTrip posts Rs 150 Cr revenue in Q3 FY25; profit declines
Medial

Online travel aggregator (OTA) platform EaseMyTrip announced its financial results on Friday for the third quarter of FY25. The results show a marginal decrease in scale and profit year-on-year. EaseMyTrip’s operating revenue decreased by 6.3% to Rs 150 crore in Q3 FY25 from Rs 160 crore in Q3 FY24, as per its unaudited consolidated financial statements filed with the National Stock Exchange (NSE). Revenue from air ticketing accounted for 65% of the revenue whereas hotel packages formed 22% of the total collection. To the tune of scale, its total expense increased by 2.4% to Rs 107 crore in Q3 FY25 from Rs 105 crore in Q4 FY24. Service cost, payment gateway, employee benefit and costs were other major overheads for EaseMyTrip during the last quarter.

Download the medial app to read full posts, comements and news.